Insulin action in the double incretin receptor knockout mouse

Diabetes

Volumn 57, Issue 2, 2008, Pages 288-297

  Ayala, Julio E ^a,d   Bracy, Deanna P ^a   Hansotia, Tanya ^b   Flock, Grace ^b   Seino, Yutaka ^c   Wasserman, David H ^a   Drucker, Daniel J ^b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c KANSAI ELECTRIC POWER CO   (Japan)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; HORMONE RECEPTOR; INCRETIN; INSULIN; PROTEIN KINASE B; CELL SURFACE RECEPTOR; GASTRIC INHIBITORY POLYPEPTIDE RECEPTOR; GLUCAGON LIKE PEPTIDE RECEPTOR; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE RECEPTOR; UNCLASSIFIED DRUG;

ARTERY CLAMP; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DOUBLE INCRETIN RECEPTOR KNOCKOUT MOUSE; ENERGY EXPENDITURE; GLUCOSE CLAMP TECHNIQUE; GLUCOSE INFUSION; HYPERGLYCEMIA; HYPERINSULINEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN SYNTHESIS; KNOCKOUT MOUSE; LIPID DIET; MOUSE; MUSCLE ATROPHY; MUSCLE MASS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPECIES COMPARISON; WILD TYPE; ADIPOSE TISSUE; ANIMAL; C57BL MOUSE; CROSS BREEDING; ENERGY METABOLISM; FAT INTAKE; FEMALE; GENETICS; HISTOLOGY; HYPERINSULINISM; MALE; MOUSE MUTANT; SKELETAL MUSCLE;

ADIPOSE TISSUE; ANIMALS; CROSSES, GENETIC; DIETARY FATS; ENERGY METABOLISM; FEMALE; GLUCOSE CLAMP TECHNIQUE; HYPERINSULINISM; INSULIN; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUSCLE, SKELETAL; RECEPTORS, CELL SURFACE; RECEPTORS, GASTROINTESTINAL HORMONE; RECEPTORS, GLUCAGON;

EID: 40749104297     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db07-0704     Document Type: Article

References (37)

1. Drucker DJ: The biology of incretin hormones. Cell Metab 3:153-165, 2006
2. Drucker DJ: The role of gut hormones in glucose homeostasis. J Clin Invest 117:24-32, 2007
3. Drucker DJ: Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. Mol Endocrinol 17:161-171, 2003
4. Kim SJ, Winter K, Nian C, Tsuneoka M, Koda Y, Mcintosh CH: Glucose-dependent insulinotropic polypeptide (GIP) stimulation of pancreatic beta-cell survival is dependent upon phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB) signaling, inactivation of the forkhead transcription factor Foxo1, and down-regulation of bax expression. J Biol Chem 280:22297-22307, 2005
5. Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ: Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem 278:471-478, 2003
6. Xu G, Stoffers DA, Habener JF, Bonner-Weir S: Exendin-4 stimulates both β-cell replication and neogenesis, resulting in increased β-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48:2270-2276, 1999
7. Hui H, Nourparvar A, Zhao X, Perfetti R: Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5′-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway. Endocrinology 144:1444-1455, 2003
8. Komatsu R, Matsuyama T, Namba M, Watanabe N, Itoh H, Kono N, Tarui S: Glucagonostatic and insulinotropic action of glucagonlike peptide I-(7-36)-amide. Diabetes 38:902-905, 1989
9. Dupre J, Behme MT, Hramiak IM, McFarlane P, Williamson MP, Zabel P, McDonald TJ: Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM. Diabetes 44:626-630, 1995
10. Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R, Schmiegel WH: Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 273:E981-E988, 1997
11. Prigeon RL, Quddusi S, Paty B, D'Alessio DA: Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect. Am J Physiol Endocrinol Metab 285:E701-E707, 2003
12. Burcelin R, Da Costa A, Drucker D, Thorens B: Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor. Diabetes 50:1720-1728, 2001
13. Miyawaki K, Yamada Y, Ban N, Ihara Y, Tsukiyama K, Zhou H, Fujimoto S, Oku A, Tsuda K, Toyokuni S, Hiai H, Mizunoya W, Fushiki T, Holst JJ, Makino M, Tashita A, Kobara Y, Tsubamoto Y, Jinnouchi T, Jomori T, Seino Y: Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med 8:738-742, 2002
14. Baggio L, Kieffer TJ, Drucker DJ: Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, regulates fasting glycemia and nonenteral glucose clearance in mice. Endocrinology 141:3703-3709, 2000
15. Edwards CM, Todd JF, Mahmoudi M, Wang Z, Wang RM, Ghatei MA, Bloom SR: Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. Diabetes 48:86-93, 1999
16. Miyawaki K, Yamada Y, Yano H, Niwa H, Ban N, Ihara Y, Kubota A, Fujimoto S, Kajikawa M, Kuroe A, Tsuda K, Hashimoto H, Yamashita T, Jomori T, Tashiro F, Miyazaki J, Seino Y: Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. Proc Natl Acad Sci USA 96:14843-14847, 1999
17. Scrocchi LA, Brown TJ, MaClusky N, Brubaker PL, Auerbach AB, Joyner AL, Drucker DJ: Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med 2:1254-1258, 1996
18. Scrocchi LA, Drucker DJ: Effects of aging and a high fat diet on body weight and glucose tolerance in glucagon-like peptide-1 receptor -/- mice. Endocrinology 139:3127-3132, 1998
19. Scrocchi LA, Marshall BA, Cook SM, Brubaker PL, Drucker DJ: Identification of glucagon-like peptide 1 (GLP-1) actions essential for glucose homeostasis in mice with disruption of GLP-1 receptor signaling. Diabetes 47:632-639, 1998
20. Pederson RA, Satkunarajah M, McIntosh CH, Scrocchi LA, Flamez D, Schuit F, Drucker DJ, Wheeler MB: Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor -/- mice. Diabetes 47:1046-1052, 1998
21. Pamir N, Lynn FC, Buchan AM, Ehses J, Hinke SA, Pospisilik JA, Miyawaki K, Yamada Y, Seino Y, McIntosh CH, Pederson RA: Glucose-dependent insulinotropic polypeptide receptor null mice exhibit compensatory changes in the enteroinsular axis. Am, J Physiol Endocrinol Metab 284:E931-E939, 2003
22. Preitner F, Ibberson M, Franklin I, Binnert C, Pende M, Gjinovci A, Hansotia T, Drucker DJ, Wollheim C, Burcelin R, Thorens B: Glucoincretins control insulin secretion at multiple levels as revealed in mice lacking GLP-1 and GIP receptors. J Clin Invest 113:635-645, 2004
23. Hansotia T, Drucker DJ: GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice. Regul Pept 128:125-134, 2005
24. Hansotia T, Maida A, Flock G, Yamada Y, Tsukiyama K, Seino Y, Drucker DJ: Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure. J Clin Invest 117:143-152, 2007
25. Ayala JE, Bracy DP, Julien BM, Rottman JN, Fueger PT, Wasserman DH: Chronic treatment with sildenafil improves energy balance and insulin action in high fat-fed conscious mice. Diabetes 56:1025-1033, 2007
26. Obici S, Wang J, Chowdury R, Feng Z, Siddhanta U, Morgan K, Rossetti L: Identification of a biochemical link between energy intake and energy expenditure. J Clin Invest 109:1599-1605, 2002
27. Nelson WR, O'Hopp SJ: A semiquantitative screening test and quantitative assay for total fecal fat. Clin Chem 15:1062-1071, 1969
28. Ayala JE, Bracy DP, McGuinness OP, Wasserman DH: Considerations in the design of hyperinsulinemic-euglycemic clamps in the conscious mouse. Diabetes 55:390-397, 2006
29. Altszuler N, De Bodo RC, Steele R, Wall JS: Measurement of size and turnover rate of body glucose pool by the isotope dilution method. Am J Physiol 187:15-24, 1956
30. Fueger PT, Bracy DP, Malabanan CM, Pencek RR, Granner DK, Wasserman DH: Hexokinase II overexpression improves exercise-stimulated but not insulin-stimulated muscle glucose uptake in high-fat-fed C57BL/6J mice. Diabetes 53:306-314, 2004
31. Kraegen EW, James DE, Jenkins AB, Chisholm DJ: Dose-response curves for in vivo insulin sensitivity in individual tissues in rats. Am J Physiol 248:E353-E362, 1985
32. Laakso M, Edelman SV, Brechtel G, Baron AD: Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man: a novel mechanism for insulin resistance. J Clin Invest 85:1844-1852, 1990
33. DeFronzo RA, Ferrannini E: Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14:173-194, 1991
34. Gault VA, Irwin N, Green BD, McCluskey JT, Greer B, Bailey CJ, Harriott P, O'Harte FP, Flatt PR: Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes. Diabetes 54:2436-2446, 2005
35. Knauf C, Cani PD, Perrin C, Iglesias MA, Maury JF, Bernard E, Benhamed F, Gremeaux T, Drucker DJ, Kahn CR, Girard J, Tanti JF, Delzenne NM, Postic C, Burcelin R: Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage. J Clin Invest 115:3554-3563, 2005
36. Bullock BP, Heller RS, Habener JF: Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 137:2968-2978, 1996
37. Wei Y, Mojsov S: Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett 358:219-224, 1995